ADCINDIA stock news
This page provides real-time market news, earnings updates, and company announcements related to ADC India Communications Limited (ADCINDIA).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-03-20 10:20 IST
ADC Therapeutics SA (ADCT) Posts Fourth Quarter Loss, Surpasses Revenue Projections
101 finance2026-03-10 13:39:57
According to the latest filings submitted to the U.S. Securities and Exchange Commission (SEC), some shareholders of the biopharmaceutical company ADC Therapeutics SA may gradually sell their holdings of the company's common stock over a period of time, with the total amount reaching up to 9,834,776 shares.
老虎证券2026-03-10 21:25:04
Exelixis (EXEL) Has Fallen 2.8% Since Its Previous Earnings Report: Is a Recovery Possible?
101 finance2026-03-12 16:40:37
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Finviz2026-03-12 20:09:49
Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala
Finviz2026-03-13 13:19:02
Engineers Gate Reduces Holdings in Sabra Health Care REIT Amid Investor Focus on Rental Revenue Patterns
101 finance2026-03-13 18:42:41
CytomX's Varsetatug Masetecan (EpCAM PROBODY ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
Finviz2026-03-16 11:03:45
CytomX Therapeutics' Pivotal Trial Endpoints and Diarrhea Prophylaxis Plans Don’t Match
101 finance2026-03-16 14:42:35
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Finviz2026-03-16 20:09:45
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Finviz2026-03-16 20:09:45
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Finviz2026-03-16 20:09:45
Kyntra Bio (KYNB) Fourth Quarter 2025 Earnings Conference Call Transcript
101 finance2026-03-16 22:15:47
Akari Therapeutics Announces ADS Ratio Change
Finviz2026-03-17 20:33:50
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
Finviz2026-03-17 20:33:51
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
Finviz2026-03-17 20:33:51
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Finviz2026-03-17 21:03:49
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
Finviz2026-03-17 21:09:07
ArriVent’s Firmonertinib Approaches Critical Q2/Q3 Phase 3 Results—Pivotal Moment for EGFR-Exon 20 Insertion NSCLC Uptake
101 finance2026-03-17 21:51:46
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
Finviz2026-03-17 21:57:46
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Finviz2026-03-18 02:52:13
Zymeworks' Ziihera Approaching a Major Turning Point: Standard Treatment for First-Line GEA Set to Evolve
101 finance2026-03-18 12:19:03
PFE's Atirmociclib Second-Line Breast Cancer Trial Achieves Target, Supports Pipeline Advancement
101 finance2026-03-18 16:31:27
Innate Pharma Faces a Ticking Clock: Key 2026 Milestones Need Success Ahead of Q3 Cash Cutoff
101 finance2026-03-19 06:33:43
Zymeworks' Pan-RAS ADC Platform Could Redefine RAS Targeting as AACR Data Looms
101 finance2026-03-19 06:33:43
Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala
Finviz2026-03-13 13:19:02
Engineers Gate Reduces Holdings in Sabra Health Care REIT Amid Investor Focus on Rental Revenue Patterns
101 finance2026-03-13 18:42:41
CytomX's Varsetatug Masetecan (EpCAM PROBODY ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
Finviz2026-03-16 11:03:45
CytomX Therapeutics' Pivotal Trial Endpoints and Diarrhea Prophylaxis Plans Don’t Match
101 finance2026-03-16 14:42:35
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Finviz2026-03-16 20:09:45
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Finviz2026-03-16 20:09:45
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Finviz2026-03-16 20:09:45
Kyntra Bio (KYNB) Fourth Quarter 2025 Earnings Conference Call Transcript
101 finance2026-03-16 22:15:47
Akari Therapeutics Announces ADS Ratio Change
Finviz2026-03-17 20:33:50
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
Finviz2026-03-17 20:33:51
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
Finviz2026-03-17 20:33:51
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Finviz2026-03-17 21:03:49
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
Finviz2026-03-17 21:09:07
ArriVent’s Firmonertinib Approaches Critical Q2/Q3 Phase 3 Results—Pivotal Moment for EGFR-Exon 20 Insertion NSCLC Uptake
101 finance2026-03-17 21:51:46
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
Finviz2026-03-17 21:57:46
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Finviz2026-03-18 02:52:13
Zymeworks' Ziihera Approaching a Major Turning Point: Standard Treatment for First-Line GEA Set to Evolve
101 finance2026-03-18 12:19:03
PFE's Atirmociclib Second-Line Breast Cancer Trial Achieves Target, Supports Pipeline Advancement
101 finance2026-03-18 16:31:27
Innate Pharma Faces a Ticking Clock: Key 2026 Milestones Need Success Ahead of Q3 Cash Cutoff
101 finance2026-03-19 06:33:43
Zymeworks' Pan-RAS ADC Platform Could Redefine RAS Targeting as AACR Data Looms
101 finance2026-03-19 06:33:43
ADCINDIA stock price change
On the last trading day, ADCINDIA stock closed at 1250.00 INR, with a price change of 1.03% for the day.
Trade stock perpsADCINDIA stock detailsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more